Minerva announces enrollment of first patient in phase 2b trial of Seltorexant
Minerva Neurosciences announced enrollment of the first patient in a Phase 2b clinical trial of seltorexant (MIN-202) in patients with insomnia disorder. A total of approximately 360 patients 18 to 85 years of age will be randomized in this study at clinical sites in the U.S., EU and Japan. December 06, 2017